SCHEMBL6908418

SCHEMBL6908418

CC(C(N)=O)c1csc(NS(=O)(=O)c2cc(Cl)sc2Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNA2 P20248 1/20 0.43
CCND1 P24385 1/20 0.43
CDK2 P24941 1/20 0.43
CDK7 P50613 1/20 0.43
CCNH P51946 1/20 0.43
CCNA1 P78396 1/20 0.43
CDK6 Q00534 1/20 0.43
PFKFB3 Q16875 1/20 0.41
S100A9 P06702 4/20 0.40
CYP2C9 P11712 1/20 0.39
ACLY P53396 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
MEN1 O00255 2/20 0.37
POLB P06746 2/20 0.37
KMT2A Q03164 2/20 0.37
SGK1 O00141 4/20 0.36
APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3615693 0.74 KMT2A (0.49) TDP1CDK1CCNB1CCNA2CCND1
SCHEMBL3620528 0.74 KMT2A (0.49) TDP1CDK1CCNB1CCNA2CCND1
SCHEMBL3622320 0.72 KMT2A (0.70) CYP2C9MEN1POLBKMT2A
SCHEMBL6753769 0.66 CDK1 (0.54) TDP1CDK1CCNB1CCNA2CCND1
SCHEMBL7563876 0.65 CDK1 (0.45) TDP1CDK1CCNB1CCNA2CCND1
SCHEMBL3259225 0.65 TDP1 (0.45) TDP1CDK1CCNB1CCNA2CCND1
SCHEMBL4962530 0.64 HSD11B1 (0.58) MEN1POLBKMT2A
SCHEMBL16296008 0.64 TDP1 (0.53) TDP1CDK1CCNB1CCNA2CCND1
SCHEMBL7563873 0.64 CDK1 (0.46) TDP1CDK1CCNB1CCNA2CCND1
SCHEMBL16296180 0.64 TDP1 (0.55) TDP1CDK1CCNB1CCNA2CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 TDP1 797/4885CDK1 796/4885CCNB1 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.